BRCA2 and breast cancer: To determine clinicopathological characteristics influencing BC prognosis (disease-free survival [DFS] and disease-specific survival [DSS]), we analyzed 1133 Czech BC patients, including 234 BRCA1/BRCA2 mutation carriers and 899 non-carriers.